These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3226360)

  • 21. Acute movement disorders in the medical setting.
    Zawar I; Caro MA; Feldman L; Jimenez XF
    Int J Psychiatry Med; 2016 Jul; 51(5):395-413. PubMed ID: 28629285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The basal ganglia and movement disorders.
    Keltner NL
    Perspect Psychiatr Care; 1996; 32(1):30-2. PubMed ID: 8868851
    [No Abstract]   [Full Text] [Related]  

  • 23. [Basal ganglia lesions and neurotransmitters].
    Yoshida M
    Nihon Rinsho; 1978; 36(1):58-64. PubMed ID: 24766
    [No Abstract]   [Full Text] [Related]  

  • 24. GABAergic circuits in the basal ganglia and movement disorders.
    Galvan A; Wichmann T
    Prog Brain Res; 2007; 160():287-312. PubMed ID: 17499121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholinergic suppression of tardive dyskinesia.
    Fann WE; Lake CR; Gerber CJ; McKenzie GM
    Psychopharmacologia; 1974 Jun; 37(4):101-7. PubMed ID: 4367406
    [No Abstract]   [Full Text] [Related]  

  • 26. The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders.
    Chambers NE; Millett M; Moehle MS
    Biochem Soc Trans; 2023 Apr; 51(2):691-702. PubMed ID: 37013974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT
    Huang M; Kwon S; Rajagopal L; He W; Meltzer HY
    Psychopharmacology (Berl); 2018 Oct; 235(10):2795-2808. PubMed ID: 30066135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
    Gerlach M; Gsell W; Kornhuber J; Jellinger K; Krieger V; Pantucek F; Vock R; Riederer P
    Brain Res; 1996 Nov; 741(1-2):142-52. PubMed ID: 9001716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hemiballism and its treatment].
    Gottlieb D; Shahin D
    Harefuah; 1987 Dec; 113(12):395-6. PubMed ID: 3452580
    [No Abstract]   [Full Text] [Related]  

  • 30. [Metabolism of acetylcholine and gamma-aminobutyric acid in the basal ganglia and limbic cortex of rats at different stages in the development of alcohol dependence].
    Maslova IV; Shevchenko NV; Balakleevskiĭ AI
    Vopr Med Khim; 1986; 32(1):110-6. PubMed ID: 3953003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biochemistry of the basal ganglia and Parkinson's disease.
    Curzon G
    Postgrad Med J; 1977 Dec; 53(626):719-25. PubMed ID: 24209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptics and the corpus striatum: clinical implications.
    Stimmel GL
    Dis Nerv Syst; 1976 Apr; 37(4):219-24. PubMed ID: 1253676
    [No Abstract]   [Full Text] [Related]  

  • 33. Dopaminergic regulation of cone retinomotor movement in isolated teleost retinas: II. Modulation by gamma-aminobutyric acid and serotonin.
    Dearry A; Burnside B
    J Neurochem; 1986 Apr; 46(4):1022-31. PubMed ID: 3950617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal inhomogeneities and basal ganglia function.
    Penney JB; Young AB
    Mov Disord; 1986; 1(1):3-15. PubMed ID: 2848190
    [No Abstract]   [Full Text] [Related]  

  • 35. The pathogensis and medical treatment of extrapyramidal disease.
    Calne DB; Eisler T
    Med Clin North Am; 1979 Jul; 63(4):715-27. PubMed ID: 157413
    [No Abstract]   [Full Text] [Related]  

  • 36. Behavioral and neurochemical consequences of ibotenic acid lesion in the subthalamic nucleus of the common marmoset.
    Andrén PE; Levin ED; Liminga U; Gunne L
    Brain Res Bull; 1995; 36(3):301-7. PubMed ID: 7697384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine and basal ganglia disorders.
    O'Reilly S; Loncin M; Cooksey B
    Neurology; 1965 Nov; 15(11):980-4. PubMed ID: 5892413
    [No Abstract]   [Full Text] [Related]  

  • 38. [Neural mechanisms for the clinical syndromes of Parkinson's disease].
    Kato M
    Nihon Rinsho; 1997 Jan; 55(1):26-31. PubMed ID: 9014419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlations between chemical mediators (dopamine, serotonin, acetylcholine and gaba), muscular tone and rapidity of movement].
    Hassler R
    Rev Neurol (Paris); 1972 Jul; 127(1):51-63. PubMed ID: 4358575
    [No Abstract]   [Full Text] [Related]  

  • 40. Two novel comments on the treatment of Huntington's disease.
    Gharibzadeh S; Sarbaz Y; Banaie M; Towhidkhah F
    J Neuropsychiatry Clin Neurosci; 2009; 21(1):98-9. PubMed ID: 19359460
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.